Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meloxicam PK Food Effect and Dose Proportionality
NCT02181322Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2001
- Primary completion
- Sep 2001
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of meloxicam in osteoarthritis (OA) and rheumatoid arthritis (RA) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum measured concentration of the analyte in plasma up to 96 hours and Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity up to 96 hours. Started Jun 2001; status: completed.
02
Drugs
meloxicam
03
Conditions
osteoarthritis (OA)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02181322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02181322.